Futu Holdings Ltd vs Inovio Pharmaceuticals Inc — how do they compare? Futu Holdings Ltd trades at $105.41 (market cap $14.74B), while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). The key difference: Futu Holdings Ltd is far larger — about 187.7× Inovio Pharmaceuticals Inc's market cap, and Futu Holdings Ltd pays a 2.47% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FUTU | INO | |
|---|---|---|
Market Cap | $14.74B | $78.55M |
Sector | Financials | Health |
52-Week High | $199.04 | $2.87 |
52-Week Low | $89.76 | $0.66 |
Enterprise Value | $14.59B | $49.56M |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.
The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →